Viewing stories from November, 2017
AGM Chairman’s address and CEO presentation
Chairman’s address and the CEO’s presentation to the 2017 Annual General Meeting of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY).
NDA submission for Starpharma’s VivaGel® BV
|
BioSpectrum Asia reported on Starpharma’s NDA submission for VivaGel® BV, noting that Starpharma is one of the few Australian companies to take a locally developed product to this stage. |
NDA submission for VivaGel® BV in the US
Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that its US New Drug Application (NDA) submission for VivaGel® BV for both treatment and prevention of BV has been lodged with the FDA through a rolling submission process.